DaVita HealthCare (DVA) is a Top-Ranked Growth Stock: Should You Buy?

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Style Scores [1][2] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score identifies attractive and discounted stocks using ratios like P/E and Price/Sales [3] - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings and sales [4] - The Momentum Score helps investors capitalize on price trends, using metrics like one-week price change and monthly earnings estimate changes [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for stock selection [6] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to assist investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +23.81%, significantly outperforming the S&P 500 [8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [9][10] Company Spotlight: DaVita HealthCare - DaVita Inc. is a leading provider of dialysis services in the U.S., focusing on patients with chronic kidney failure [11] - DaVita holds a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating potential for growth [12] - The company is projected to have a year-over-year earnings growth of 12.9% for the current fiscal year, with upward revisions in earnings estimates [12] - With strong Growth and VGM Style Scores, DaVita is recommended for investors' consideration [13]